CASP2

CASP2 (ICH-1/Nedd2) is a cysteine protease that functions as a pro-apoptotic regulator, with alternative splicing of the locus producing both a death-inducing long isoform and a death-suppressing short isoform (PMID:8087842). The enzyme is synthesized as an inactive precursor that must dimerize—a step requiring both the prodomain and the carboxyl-terminal residues—before undergoing proteolytic processing at defined aspartate residues to generate active p19+p12 subunits, with dimerization preceding processing and self-processing correlating with death induction (PMID:9506977). The prodomain additionally serves as a nuclear localization signal, sufficient to redirect normally cytoplasmic caspase-3 to the nucleus (PMID:9733748). CASP2 is activated early in apoptosis, ahead of effector caspases (PMID:9148927), and cleaves PARP in a manner identical to that seen in apoptotic cells (PMID:7642516); its own precursor is processed by caspase-1, caspase-3, and granzyme B, integrating it into both intrinsic apoptotic and cytotoxic lymphocyte killing pathways (PMID:9078393). Genetic loss-of-function studies establish CASP2 as a required mediator of trophic factor (NGF/serum) deprivation-induced death in neurons, but not of all apoptotic stimuli, and in this paradigm it acts independently of caspase-3-like activity (PMID:9045720, PMID:9801360). Beyond apoptosis, CASP2 acts as an endogenous repressor of autophagy through the AMPK/mTOR/MAPK pathway, with its loss elevating ROS as an upstream autophagy-inducing signal (PMID:24879153). Biallelic truncating CASP2 variants cause a neurodevelopmental disorder with lissencephaly and pachygyria, implicating its PIDDosome activity in human cortical development (PMID:37880421).

1. 1994 High

   Established that a single caspase locus can encode opposing regulators of cell death, defining CASP2's dual potential through alternative splicing.

   Evidence Overexpression of ICH-1L vs ICH-1S isoforms in mammalian cells with death assays

   PMID:8087842

   Open questions at the time

   • Physiological balance of the two isoforms in vivo not established
   • Substrates and catalytic mechanism not yet defined
2. 1994 High

   Positioned CASP2 within the apoptotic hierarchy by showing BCL-2 suppresses CASP2-induced death.

   Evidence Overexpression in fibroblast and neuroblastoma cells with BCL-2 rescue

   PMID:7958843

   Open questions at the time

   • Whether BCL-2 acts directly on CASP2 or upstream not resolved
   • Endogenous requirement not tested by this gain-of-function approach
3. 1995 Medium

   Demonstrated an endogenous pro-apoptotic requirement for CASP2 beyond overexpression, and identified PARP as a substrate.

   Evidence Antisense suppression in FDC-P1 cells; COS co-transfection and in vitro cleavage of PARP with recombinant enzyme

   PMID:7615091 PMID:7642516

   Open questions at the time

   • Antisense specificity from a single lab/method
   • Full substrate repertoire unknown
4. 1996 High

   Defined how the CASP2 precursor is activated, placing it as a substrate of upstream proteases including granzyme B.

   Evidence In vitro cleavage of the p51 precursor by caspase-3, caspase-1, Mch2, Nedd2, and granzyme B with inhibitor controls

   PMID:9078393

   Open questions at the time

   • Relative physiological contribution of each protease unknown
   • Order of CASP2 relative to these proteases in cells not resolved
5. 1997 High

   Established a stimulus-specific, non-redundant role for CASP2 in neuronal apoptosis driven by trophic factor withdrawal.

   Evidence Antisense knockdown in PC12 cells and sympathetic neurons; comparison across distinct death stimuli

   PMID:9045720

   Open questions at the time

   • Molecular trigger linking trophic deprivation to CASP2 activation unknown
   • Downstream effectors in neurons not mapped
6. 1997 Medium

   Provided temporal evidence that CASP2 activation precedes effector caspase activation, implying an apical position.

   Evidence Western detection of processed subunits across multiple stimuli and resistant cell lines

   PMID:9148927

   Open questions at the time

   • No direct epistasis experiment
   • Activation timing differs by stimulus
7. 1998 High

   Resolved the activation mechanism—dimerization requiring prodomain and C-terminus precedes aspartate processing—and uncovered prodomain-directed nuclear targeting.

   Evidence Yeast two-hybrid dimerization, aspartate mutagenesis, in vitro processing; GFP fusions and caspase-3 domain swaps

   PMID:9506977 PMID:9733748

   Open questions at the time

   • Physiological dimerization platform (e.g. activating complex) not identified here
   • Functional consequence of nuclear localization for specific substrates unclear
8. 1998 High

   Showed CASP2-dependent neuronal death and D333 processing proceed independently of caspase-3-like activity, refining the apical-vs-effector question.

   Evidence Selective caspase inhibitors and antisense in trophic-deprived PC12 cells and sympathetic neurons

   PMID:9801360

   Open questions at the time

   • Identity of the executioner downstream of CASP2 in neurons unresolved
   • Apparent conflict with general upstream-of-caspase-3 model not reconciled across paradigms
9. 2014 Medium

   Identified a non-apoptotic function: CASP2 represses autophagy via AMPK/mTOR/MAPK signaling, with ROS as an upstream cue.

   Evidence Casp2 knockout/knockdown/re-insertion in MEFs and tissues; autophagy and ROS markers

   PMID:24879153

   Open questions at the time

   • Direct substrate or protein target linking CASP2 to the pathway not identified
   • Single-lab finding
10. 2023 Medium

    Linked CASP2 loss-of-function to human disease, implicating its PIDDosome role in cortical development.

    Evidence Exome sequencing, RNA splice analysis, and family segregation in lissencephaly/pachygyria patients

    PMID:37880421

    Open questions at the time

    • No in vitro reconstitution of PIDDosome dysfunction
    • Mechanism connecting CASP2 to neuronal migration not established
11. 2024 Low

    Described dual transcriptional/post-transcriptional control of CASP2 in cancer cells uncoupling its mRNA induction from protein output.

    Evidence Reporter assays, knockdown/overexpression of E2F1 and HuR in esophageal adenocarcinoma cells

    PMID:39524140

    Open questions at the time

    • Single study with limited orthogonal validation
    • Generality beyond esophageal adenocarcinoma unknown

• The molecular composition and activating platform of the human CASP2/PIDDosome and how it connects to both cortical development and autophagy repression remain unresolved.
• No reconstituted human PIDDosome in the corpus
• Direct CASP2 substrate(s) in autophagy and neurodevelopment not identified